

hydrolysis of 2-acetylaminofluorene (I). The extent of hydrolysis was determined by diazotizing the resulting free amine (II) and coupling with the disodium salt of 2-naphthol-3,6-disulphonic acid, using a modification of the colorimetric method described by Westfall¹⁰.

Table 1. HYDROLYSIS AND CARCINOGENICITY OF DERIVATIVES OF 2-AMINOFLUORENE

Structure	NHR	m.p.*	Anal. Found†			% Hydrolysis	Carcinogenicity
			C	H	N		
I ^{1,14}	CH ₃ CO-	194				100	+++
II ^{1,14}	H-	127					+++
III ²	C ₆ H ₅ CO-	219-220				26.8	+
IV	<i>o</i> -CH ₃ = C ₆ H ₄ CO-	219-220	84.40	5.55	4.82	7.0	
V	<i>m</i> -CH ₃ - C ₆ H ₄ CO-	192-193	84.37	5.67	4.85	24.8	
VI	<i>p</i> -CH ₃ - C ₆ H ₄ CO-	217-218	84.22	5.64	4.63	22.6	
VII	<i>o</i> -HOOC- C ₆ H ₄ CO-	298-299				92.7	
VIII ¹⁵	NH ₂ CH ₂ - CO-	188-189				53.0	++
IX ^{4,16}	<i>p</i> -CH ₃ - C ₆ H ₄ SO ₂ -	160-161				4.9	0

* All melting points are uncorrected.

† Anal. Calc. C, 84.25; H, 5.72; N, 4.68 (Analyses by Rowland Chemical Lab.).

The results (Table 1) show that there is a considerable difference in the ease of hydrolysis *in vitro*. The acetyl derivative (I), is the most easily hydrolysed of the compounds studied. This is closely followed by the phthaloyl (VII). The tosyl is hydrolysed to the least extent.

It is known that I is very carcinogenic while III is only slightly active¹¹. It might be predicted that any 2-aminofluorene derivative which is hydrolysed to the extent of about 50 per cent or more under the conditions of this experiment would be quite carcinogenic. Thus, the phthaloyl derivative, VII, would be expected to be as carcinogenic as I or II, while the glycol derivative (VIII) would be moderately active. The *m*- and *p*-toluoyl derivatives should be comparable to the benzoyl derivative (III) and have a much lower carcinogenicity than I or II. The tosyl derivative (IX) is non-carcinogenic¹². The *o*-toluoyl derivative (IV) is hydrolysed to only a slightly greater extent, 7.0 versus 4.9 per cent. It is predicted that this will have little detectable activity.

To test these carcinogenicity predictions, one of the previously untested compounds, 2-glycylaminofluorene (VIII)* was administered by stomach tube (3 mgm. in 1 ml. 1 per cent methylcellulose 5 times weekly for 20 weeks) to young adult male Wistar rats. Six of 20 rats so treated developed cystic cholangiomas, with the first tumour appearing at 57 weeks. In a group of 23 rats receiving the same dose of I, 10 rats developed liver tumours; the first tumour was found at 29 weeks. Thus, the latent period for liver carcinogenesis by VIII is practically twice that of I. As predicted by the hydrolysis data, VIII is a carcinogen having a moderate activity compared to I.

A study of the relative carcinogenicities of IV, V, VI and VII is being made by Dr. H. P. Morris of the National Cancer Institute.

We are grateful to Charles J. Osterholt, jun., and Martin Nemerow for technical assistance and to L. H. Rombach and I. R. MacGregor for a sample of compound VIII. This work was supported by research grants C-1356 and C-1066 from the National

* In their review² Weisburger and Weisburger state that carcinogenicity data on this compound have been published by Hirs (ref. 13). However, the compound synthesized by Hirs and tested by Twombly was actually N-(2-fluorenyl)-glycine and not 2-glycylaminofluorene.

Cancer Institute, National Institutes of Health, U.S. Public Health Service.

MARY F. ARGUS
FRANCIS E. RAY

Cancer Research Laboratory,
University of Florida,
Gainesville, Florida.

- Wilson, R. H., DeEds, F., and Cox, A. J., *Cancer Res.*, **1**, 595 (1941).
- Weisburger, E. K., and Weisburger, J. H., in Vol. 5 'Advances in Cancer Research', edit. by Greenstein, J. P., and Haddow, A., 361 (Academic Press Inc., New York, 1958).
- Newell, M. P. (in preparation).
- Ray, F. E., and Argus, M. F., *Cancer Res.*, **11**, 783 (1951).
- Ray, F. E., and Geiser, R. C., *Cancer Res.*, **10**, 616 (1950).
- Morris, H. P., Weisburger, J. H., and Weisburger, E. K., *Cancer Res.*, **10**, 620 (1950).
- Weisburger, J. H., Weisburger, E. K., and Morris, H. P., *J. Nat. Cancer Inst.*, **11**, 797 (1951).
- Gutmann, H. R., and Peters, J. H., *J. Biol. Chem.*, **211**, 63 (1954).
- Weisburger, J. H., *Biochim. et Biophys. Acta*, **16**, 382 (1955).
- Westfall, B. B., *J. Nat. Cancer Inst.*, **6**, 23 (1945).
- Morris, H. P. (in preparation).
- Gutmann, H. R., and Peters, J. H., *Cancer Res.*, **13**, 415 (1953).
- Hirs, C. H. W., *J. Amer. Chem. Soc.*, **71**, 1893 (1949).
- Strasburger, J., *Ber.*, **16**, 2346 (1883).
- Rombach, L. H., and MacGregor, I. R., *J. Org. Chem.*, **19**, 428 (1954).
- Campbell, N., Anderson, W., and Gilmore, J., *J. Chem. Soc.*, 466 (1940).

Changes in the Level of Serum Protein during Treatment of Kwashiorkor

CHANGES in the level of serum proteins during the dietary treatment of kwashiorkor have been reported¹. As these changes appear to be a consistent feature of the recovery process, it was thought desirable to place them on a statistical basis.

Examination of the results of analyses of the serum of some 429 cases of kwashiorkor, before and after treatment in Nigeria, gave the following results:

	Before treatment (gm./100 ml.)	Upon recovery (gm./100 ml.)
(Means) Total proteins	4.27 ± 0.84	6.5 ± 1.01
Serum albumin	1.7 ± 0.54	3.5 ± 0.77
Coefficient of correlation between total proteins and serum albumin	0.59	0.73
Coefficient of correlation between total proteins and serum globulins	0.45	0.48

It seems, therefore, that the concentration of serum γ -globulin is independent of the total protein-level during the treatment of kwashiorkor. On the other hand, the imbalance in the relationship between total serum proteins and albumin, in the acute phase of the disease, is corrected during treatment by increasing the concentration of the latter in the direction of restoring the proportionality between the two.

These data may serve as an accurate means of determining the prognosis in cases of kwashiorkor under nutritional care.

My thanks are due to Dr. Collis and Dr. Hills of the University College Hospital, Ibadan, for allowing me to consult their clinical records.

OLUMBE BASSIR

Biochemistry Laboratory,
University College, Ibadan.
Sept. 8.

¹ Senecal, J., *Ann. New York Acad. Sci.*, **69**, 916 (1958).

Oleuropeic Acid: a New Compound from *Olea europaea*

WE have recently announced¹ the isolation of oleuropein from *Olea europaea* which proved to be a double ester of glucose with protocatechuic acid and a second, as yet undescribed, non-aromatic acid. We have now succeeded in elucidating the structure of this compound—oleuropeic acid. It could be isolated by alkaline hydrolysis of oleuropein with subsequent fractionation of the hydrolysate from different solvents.